All articles by Frankie Fattorini

Frankie Fattorini

Frankie Fattorini is a healthcare and pharmaceutical reporter. His background is in genomics research, and he has also worked in medical communications. Frankie has written freelance articles on emerging technologies and various pieces on oncology and drug development.

The slow march of clinical biomarkers to become surrogate endpoints

Clinicians have often pushed for certain biomarkers to move from serving a purely informative role in clinical trials to becoming…
The innovators working to make in vivo cell therapy a reality

As investors signal early interest in in vivo cell therapies and raise the modality’s potential for commercial success, a growing…
Researchers become scientific tastemakers by handing more R&D to autonomous labs

Pharmaceutical R&D is falling increasingly to artificial intelligence (AI)-guided autonomous laboratories, and the people behind them say the role of…
Europe’s pharma trade with the US remains critical despite tariff turmoil

US government policies of Most Favored Nation (MFN) and tariffs threaten to disrupt Europe’s pharmaceutical trade, but while European countries…
Podcast: Rare Disease Day: FDA guidance allowing advancement

It’s been a busy year for rare disease developers, with the US Food and Drug Administration (FDA) releasing several new…

Pharma eyes AI deals to stem lost revenues from patent expirations

Pharmaceutical giants are employing an array of tactics to minimise the falling revenues that come when patents expire on their…
Why pharma manufacturers are still investing in Europe

Undeterred by tariffs and global competition, pharma manufacturers are seeing an opportunity in Europe and continuing to invest accordingly. Europe’s…
JPM26: Fujifilm’s modular manufacturing answer to pharma tariffs

Fujifilm Biotechnology’s system of setting up similar manufacturing facilities across the globe —termed the ‘KojoX’ approach — has allowed the…
JPM26: Bayer evades patent cliff in a way it may not be able to repeat

Bayer is re-entering key assets in the US market under new indications to reclaim lost profits from patent expirations for…
JPM26: 2025 a “breakout year” for rare disease biotechs

Developers in rare disease emphasise cashflow and R&D expansion as evidence of their transition from emerging biotechs to established companies…